Updated Strattera Label Will Include "Black Box" Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly will add a "black box" warning to the product label for Strattera to communicate information on reports of suicidal thoughts among children and adolescents treated with the attention deficit/hyperactivity disorder medication
You may also be interested in...
Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More
Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.
FDA Issues Strattera Public Health Advisory On Suicidal Thinking
Advisory alerts physicians to the risk of suicidal thinking in children and adolescents related to use of Eli Lilly's ADHD therapy atomoxetine.
FDA Issues Strattera Public Health Advisory On Suicidal Thinking
Advisory alerts physicians to the risk of suicidal thinking in children and adolescents related to use of Eli Lilly's ADHD therapy atomoxetine.